Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00970502 · OUTCOME

Toxicity

Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer · Source last updated 2017-04-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
30 DAYS

What was measured

Number of participants with acute and late toxicity

Analysis population: Erlotinib and celecoxib were administered orally

Groups in this outcome

Celecoxib 200mg

Dose Level 1: Patients administered 150mg Erlotinib daily and 200mg Celecoxib twice daily

Celecoxib 400mg

Dose Level 2: Patients administered 150mg Erlotinib daily and 400mg Celecoxib twice daily

Celecoxib 600mg

Dose Level 3: Patients administered 150mg Erlotinib daily and 600mg Celecoxib twice daily

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Celecoxib 200mg3
Celecoxib 400mg8
Celecoxib 600mg3

Reported measurements

Source class 1
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Celecoxib 200mg0Not reportedNot reportedNot reportedNot reported
Celecoxib 400mg1Not reportedNot reportedNot reportedNot reported
Celecoxib 600mg2Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        1
      3. group Id
        OG002
        value
        2
denoms
  1. counts
    1. group Id
      OG000
      value
      3
    2. group Id
      OG001
      value
      8
    3. group Id
      OG002
      value
      3
    units
    Participants
description
Number of participants with acute and late toxicity
groups
  1. description
    Dose Level 1: Patients administered 150mg Erlotinib daily and 200mg Celecoxib twice daily
    id
    OG000
    title
    Celecoxib 200mg
  2. description
    Dose Level 2: Patients administered 150mg Erlotinib daily and 400mg Celecoxib twice daily
    id
    OG001
    title
    Celecoxib 400mg
  3. description
    Dose Level 3: Patients administered 150mg Erlotinib daily and 600mg Celecoxib twice daily
    id
    OG002
    title
    Celecoxib 600mg
param Type
NUMBER
population Description
Erlotinib and celecoxib were administered orally
reporting Status
POSTED
time Frame
30 DAYS
title
Toxicity
type
PRIMARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice